Patents by Inventor Gilles Salles

Gilles Salles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD19 antibody having ADCC function with improved glycosylation profile
    Patent number: 9120856
    Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: September 1, 2015
    Assignees: INTERNATIONAL-DRUG-DEVELOPMENT BIOTECH, UCBL UNIVERSITE CLAUDE BERNARD DE LYON 1, HOSPICES CIVILS DE LYON
    Inventors: Gilles Salles, Claudine Vermot-Desroches
  • ANTI-CD19 ANTIBODY HAVING ADCC FUNCTION WITH IMPROVED GLYCOSYLATION PROFILE
    Publication number: 20130183306
    Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialic acid, high ADCC function and no CDC. The present invention also relates to the use of these antibodies in the treatment, prevention or management of diseases or disorders, such as cancer, especially a B-cell malignancy and auto-immune disease.
    Type: Application
    Filed: July 18, 2011
    Publication date: July 18, 2013
    Applicants: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1
    Inventors: Gilles Salles, Claudine Vermot-Desroches